The effects of COX-2 inhibitor during osteogenic differentiation of bone marrow-derived human mesenchymal stem cells

Dong Suk Yoon, Je Hyun Yoo, Yun Hee Kim, Seungil Paik, Chang Dong Han, Jin Woo Lee

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Cyclooxygenase-2 (COX-2) inhibitors suppress bone repair and bone formation by suppressing angiogenesis as well as potentially interfering with osteoblast and osteoclast functions. In spite of these reports, there is a controversy over the exact effects of COX-2 inhibitors on bone formation processes itself. This work was designed to investigate the effect of COX-2 inhibitor on osteogenesis of human bone marrow-derived mesenchymal stem cells (MSC). MSCs in osteogenesis were treated with COX-2 inhibitor (celecoxib and naproxen) in the absence or presence of interleukin-1β (IL-1β), which was used to induce inflammation. Following differentiation, alkaline phosphatase (ALP) and calcium contents of IL-1β-treated MSC were significantly reduced by high doses of COX-2 inhibitors compared with the low-dose group. However, in non-inflammatory-conditioned MSCs, ALP and calcium contents were not reduced by COX-2 inhibitors. The mRNA expression of Runx2/Cbfα1, Dlx5, and osteocalcin was also decreased by COX-2 inhibitors in inflammatory-conditioned MSCs and showed a significant decrease for the high dose while they remained constant in the non-inflammatory-conditioned MSCs. These data indicate that the osteogenic potential of MSC is inhibited/delayed by the treatment of high-dose NSAIDs under inflammatory conditions.

Original languageEnglish
Pages (from-to)1523-1533
Number of pages11
JournalStem Cells and Development
Volume19
Issue number10
DOIs
Publication statusPublished - 2010 Oct 1

Fingerprint

Cyclooxygenase 2 Inhibitors
Mesenchymal Stromal Cells
Bone Marrow
Osteogenesis
Celecoxib
Interleukin-1
Alkaline Phosphatase
Calcium
Naproxen
Osteocalcin
Non-Steroidal Anti-Inflammatory Agents
Osteoclasts
Osteoblasts
Inflammation
Bone and Bones
Messenger RNA

All Science Journal Classification (ASJC) codes

  • Hematology
  • Developmental Biology
  • Cell Biology

Cite this

Yoon, Dong Suk ; Yoo, Je Hyun ; Kim, Yun Hee ; Paik, Seungil ; Han, Chang Dong ; Lee, Jin Woo. / The effects of COX-2 inhibitor during osteogenic differentiation of bone marrow-derived human mesenchymal stem cells. In: Stem Cells and Development. 2010 ; Vol. 19, No. 10. pp. 1523-1533.
@article{b6136323811f4dc29be1f0ad73e5bc8c,
title = "The effects of COX-2 inhibitor during osteogenic differentiation of bone marrow-derived human mesenchymal stem cells",
abstract = "Cyclooxygenase-2 (COX-2) inhibitors suppress bone repair and bone formation by suppressing angiogenesis as well as potentially interfering with osteoblast and osteoclast functions. In spite of these reports, there is a controversy over the exact effects of COX-2 inhibitors on bone formation processes itself. This work was designed to investigate the effect of COX-2 inhibitor on osteogenesis of human bone marrow-derived mesenchymal stem cells (MSC). MSCs in osteogenesis were treated with COX-2 inhibitor (celecoxib and naproxen) in the absence or presence of interleukin-1β (IL-1β), which was used to induce inflammation. Following differentiation, alkaline phosphatase (ALP) and calcium contents of IL-1β-treated MSC were significantly reduced by high doses of COX-2 inhibitors compared with the low-dose group. However, in non-inflammatory-conditioned MSCs, ALP and calcium contents were not reduced by COX-2 inhibitors. The mRNA expression of Runx2/Cbfα1, Dlx5, and osteocalcin was also decreased by COX-2 inhibitors in inflammatory-conditioned MSCs and showed a significant decrease for the high dose while they remained constant in the non-inflammatory-conditioned MSCs. These data indicate that the osteogenic potential of MSC is inhibited/delayed by the treatment of high-dose NSAIDs under inflammatory conditions.",
author = "Yoon, {Dong Suk} and Yoo, {Je Hyun} and Kim, {Yun Hee} and Seungil Paik and Han, {Chang Dong} and Lee, {Jin Woo}",
year = "2010",
month = "10",
day = "1",
doi = "10.1089/scd.2009.0393",
language = "English",
volume = "19",
pages = "1523--1533",
journal = "Stem Cells and Development",
issn = "1547-3287",
publisher = "Mary Ann Liebert Inc.",
number = "10",

}

The effects of COX-2 inhibitor during osteogenic differentiation of bone marrow-derived human mesenchymal stem cells. / Yoon, Dong Suk; Yoo, Je Hyun; Kim, Yun Hee; Paik, Seungil; Han, Chang Dong; Lee, Jin Woo.

In: Stem Cells and Development, Vol. 19, No. 10, 01.10.2010, p. 1523-1533.

Research output: Contribution to journalArticle

TY - JOUR

T1 - The effects of COX-2 inhibitor during osteogenic differentiation of bone marrow-derived human mesenchymal stem cells

AU - Yoon, Dong Suk

AU - Yoo, Je Hyun

AU - Kim, Yun Hee

AU - Paik, Seungil

AU - Han, Chang Dong

AU - Lee, Jin Woo

PY - 2010/10/1

Y1 - 2010/10/1

N2 - Cyclooxygenase-2 (COX-2) inhibitors suppress bone repair and bone formation by suppressing angiogenesis as well as potentially interfering with osteoblast and osteoclast functions. In spite of these reports, there is a controversy over the exact effects of COX-2 inhibitors on bone formation processes itself. This work was designed to investigate the effect of COX-2 inhibitor on osteogenesis of human bone marrow-derived mesenchymal stem cells (MSC). MSCs in osteogenesis were treated with COX-2 inhibitor (celecoxib and naproxen) in the absence or presence of interleukin-1β (IL-1β), which was used to induce inflammation. Following differentiation, alkaline phosphatase (ALP) and calcium contents of IL-1β-treated MSC were significantly reduced by high doses of COX-2 inhibitors compared with the low-dose group. However, in non-inflammatory-conditioned MSCs, ALP and calcium contents were not reduced by COX-2 inhibitors. The mRNA expression of Runx2/Cbfα1, Dlx5, and osteocalcin was also decreased by COX-2 inhibitors in inflammatory-conditioned MSCs and showed a significant decrease for the high dose while they remained constant in the non-inflammatory-conditioned MSCs. These data indicate that the osteogenic potential of MSC is inhibited/delayed by the treatment of high-dose NSAIDs under inflammatory conditions.

AB - Cyclooxygenase-2 (COX-2) inhibitors suppress bone repair and bone formation by suppressing angiogenesis as well as potentially interfering with osteoblast and osteoclast functions. In spite of these reports, there is a controversy over the exact effects of COX-2 inhibitors on bone formation processes itself. This work was designed to investigate the effect of COX-2 inhibitor on osteogenesis of human bone marrow-derived mesenchymal stem cells (MSC). MSCs in osteogenesis were treated with COX-2 inhibitor (celecoxib and naproxen) in the absence or presence of interleukin-1β (IL-1β), which was used to induce inflammation. Following differentiation, alkaline phosphatase (ALP) and calcium contents of IL-1β-treated MSC were significantly reduced by high doses of COX-2 inhibitors compared with the low-dose group. However, in non-inflammatory-conditioned MSCs, ALP and calcium contents were not reduced by COX-2 inhibitors. The mRNA expression of Runx2/Cbfα1, Dlx5, and osteocalcin was also decreased by COX-2 inhibitors in inflammatory-conditioned MSCs and showed a significant decrease for the high dose while they remained constant in the non-inflammatory-conditioned MSCs. These data indicate that the osteogenic potential of MSC is inhibited/delayed by the treatment of high-dose NSAIDs under inflammatory conditions.

UR - http://www.scopus.com/inward/record.url?scp=77957593126&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77957593126&partnerID=8YFLogxK

U2 - 10.1089/scd.2009.0393

DO - 10.1089/scd.2009.0393

M3 - Article

C2 - 20095820

AN - SCOPUS:77957593126

VL - 19

SP - 1523

EP - 1533

JO - Stem Cells and Development

JF - Stem Cells and Development

SN - 1547-3287

IS - 10

ER -